{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:58:58Z","timestamp":1792004338175,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.euroneuro.2024.07.005","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T15:55:46Z","timestamp":1721231746000},"page":"18-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition"],"prefix":"10.1016","volume":"87","author":[{"given":"Sydney H.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-3271","authenticated-orcid":false,"given":"Anthony O.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9501-9366","authenticated-orcid":false,"given":"Philip D.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay B.","family":"Saoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-1719","authenticated-orcid":false,"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramana","family":"Kuchibhatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Luthringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2024.07.005_bib0001","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/schbul\/sby050","article-title":"Cross-cultural validation of the 5-factor structure of negative symptoms in schizophrenia","volume":"45","author":"Ahmed","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0002","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/schbul\/sbab148","article-title":"Two factors, five factors, or both? External validation studies of negative symptom dimensions in schizophrenia","volume":"48","author":"Ahmed","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1017\/S0033291721004451","article-title":"Mechanisms of cognitive-behavioral therapy effects on symptoms of body dysmorphic disorder: a network intervention analysis","volume":"53","author":"Bernstein","year":"2023","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/schbul\/sbq104","article-title":"Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia","volume":"37","author":"Blanchard","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000495045","article-title":"Introducing network intervention analysis to investigate sequential, symptom-specific treatment effects: a demonstration in co-occurring insomnia and depression","volume":"88","author":"Blanken","year":"2019","journal-title":"PsychOther Psychosom."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/wps.20375","article-title":"A network theory of mental disorders","volume":"16","author":"Borsboom","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0007","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","article-title":"Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia","volume":"174","author":"Davidson","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0008","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/sbac013","article-title":"Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia","volume":"48","author":"Davidson","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0009","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1037\/met0000167","article-title":"A tutorial on regularized partial correlation networks","volume":"23","author":"Epskamp","year":"2018","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eurpsy.2014.01.007","article-title":"Impact of primary negative symptoms on functional outcomes in schizophrenia","volume":"29","author":"Fervaha","year":"2014","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0011","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/schbul\/sbn094","article-title":"Negative symptoms in schizophrenia: avolition and Occam's razor","volume":"36","author":"Foussias","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0012","series-title":"glasso: Graphical Lasso-Estimation of Gaussian Graphical Models. R Package Version 1","author":"Friedman","year":"2014"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0013","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0014","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0015","unstructured":"Haslbeck, J., Waldorp, L.J., 2015. mgm: Estimating time-varying mixed graphical models in high-dimensional data. arXiv preprint arXiv:1510.06871."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0016","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3758\/s13428-017-0910-x","article-title":"How well do network models predict observations? On the importance of predictability in network models","volume":"50","author":"Haslbeck","year":"2018","journal-title":"Behav. Res. Methods"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0017","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/1745691616639283","article-title":"A complex network perspective on clinical science","volume":"11","author":"Hofmann","year":"2016","journal-title":"Perspect. Psychol. Sci."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0018","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0019","first-page":"30","article-title":"Negative symptom dimensions of the positive and negative syndrome scale across geographical regions: implications for social, linguistic, and cultural consistency","volume":"14","author":"Khan","year":"2017","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: psychometric properties","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0021","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0022","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brat.2016.06.006","article-title":"Can network analysis transform psychopathology?","volume":"86","author":"McNally","year":"2016","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-clinpsy-081219-092850","article-title":"Network analysis of psychopathology: controversies and challenges","volume":"17","author":"McNally","year":"2021","journal-title":"Annu Rev. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0024","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.psychres.2012.02.018","article-title":"Negative symptoms in individuals at clinical high risk of psychosis","volume":"196","author":"Piskulic","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2023.03.028","article-title":"Long-term effects of Roluperidone on negative symptoms of schizophrenia","volume":"255","author":"Rabinowitz","year":"2023","journal-title":"Schizophr. Res."},{"issue":"Suppl 20","key":"10.1016\/j.euroneuro.2024.07.005_bib0026","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0027","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/schbul\/sby169","article-title":"Reconsidering the latent structure of negative symptoms in schizophrenia: a review of evidence supporting the 5 consensus domains","volume":"45","author":"Strauss","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0028","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41537-021-00145-4","article-title":"Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development","volume":"7","author":"Strauss","year":"2021","journal-title":"npj Schizophrenia"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0029","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/schbul\/sbx066","article-title":"A transdiagnostic review of negative symptom phenomenology and etiology","volume":"43","author":"Strauss","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0030","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/schbul\/sbn167","article-title":"Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study","volume":"36","author":"Strauss","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0031","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.comppsych.2012.05.009","article-title":"Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia","volume":"53","author":"Strauss","year":"2012","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.07.005_bib0032","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/schbul\/sbz141","article-title":"Network analysis indicates that avolition is the most central domain for the successful treatment of negative symptoms: evidence from the roluperidone randomized clinical trial","volume":"46","author":"Strauss","year":"2020","journal-title":"Schizophr. Bull."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24001603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24001603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T02:40:44Z","timestamp":1725763244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X24001603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"alternative-id":["S0924977X24001603"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.07.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}